Results 111 to 118 of about 490 (118)
Some of the next articles are maybe not open access.
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Nature Reviews Clinical Oncology, 2013Joaquin Mateo +2 more
exaly
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Nature Medicine, 2018Yuting Sun +2 more
exaly
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Nature Reviews Cancer, 2008Ludger Hengst, Joyce M Slingerland
exaly
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nature Reviews Clinical Oncology, 2017Mizuki Nishino +2 more
exaly
The evolving landscape of tissue‐agnostic therapies in precision oncology
Ca-A Cancer Journal for CliniciansVivek Subbiah +2 more
exaly
Interplay between β-lactamases and new β-lactamase inhibitors
Nature Reviews Microbiology, 2019Karen Bush, Patricia A Bradford
exaly
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Nature, 2009Michael A Milhollen +2 more
exaly
SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN
Ca-A Cancer Journal for Clinicians, 2005exaly